Recent Advances in Non-muscle Invasive Bladder Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 1272
Special Issue Editor
Special Issue Information
Dear Colleagues,
Non-muscle invasive bladder cancer represents a wide disease spectrum. Risk stratification based on tumor size, number, grade, and T stage guides treatment and surveillance protocols. Continued advancements have led to a rapid evolution in the management of non-muscle invasive disease. Endoscopic techniques have expanded past traditional monopolar resection to include en-bloc laser-based resections. More options are now available to enhance disease surveillance following resection, including enhanced cystoscopy and new urine-based markers to evaluate for disease recurrence. Multiple efforts have been completed and are underway to expand options for adjuvant therapy following tumor resection. This includes BCG naive intermediate and high-risk non-muscle invasive disease and BCG refractory disease. Trials evaluating intravesical therapy include viral-based treatment, chemotherapy, and the combination of systemic immunotherapy and targeted therapy. This Special Issue will highlight the current state of the art in the diagnosis, management and surveillance of non-muscle invasive bladder cancer
Prof. Dr. Paul L. Crispen
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-muscle invasive bladder cancer
- adjuvant therapy
- surveillance
- BCG refractory
- intravesical therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
